Samsung Biologics Co.,Ltd.

Total Valuation

Samsung Biologics Co.,Ltd. carries a market capitalization of 65.04T, placing it among publicly traded companies globally. Its enterprise value stands at 81.61T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Samsung Biologics Co.,Ltd. currently has 46.29M shares outstanding.

Valuation Ratios

Samsung Biologics Co.,Ltd. trades at a trailing price-to-earnings ratio of 43.70. The price-to-sales ratio is 18.17, and the price-to-book ratio stands at 11.01.

Enterprise Valuation

On an enterprise value basis, Samsung Biologics Co.,Ltd. trades at an EV/EBITDA multiple of 37.73 and an EV/FCF ratio of 24.96. The EV/Sales ratio of 18.07 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 37.73 provides insight into valuation relative to core operating earnings.

Financial Position

Samsung Biologics Co.,Ltd. maintains a current ratio of 1.70, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.08, indicating elevated leverage, while an interest coverage ratio of 81.94 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Samsung Biologics Co.,Ltd. posts a return on equity of 28.68 and a return on invested capital of 14.55.

Taxes

Over the trailing twelve months, Samsung Biologics Co.,Ltd. has paid 551.82B in income taxes, reflecting an effective tax rate of 24.42.

Stock Price Statistics

Samsung Biologics Co.,Ltd.'s stock has declined approximately -11.1954% over the past 52 weeks. The 50-day moving average sits at 1.40M, while the 200-day moving average is 1.63M.

Income Statement

Over the trailing twelve months, Samsung Biologics Co.,Ltd. generated 4.52T in revenue and converted that into 1.88T in net income, yielding earnings per share of 31,300.58. EBITDA reached 2.16T, while operating income came in at 2.16T.

Balance Sheet

Samsung Biologics Co.,Ltd. holds 1.65T in cash and equivalents against 1.19T in total debt, resulting in a net debt position of 398.54B. Total book value stands at 7.46T, with working capital of 1.92T providing operational flexibility.

Cash Flow

Samsung Biologics Co.,Ltd. produced 2.33T in operating cash flow over the past twelve months. After subtracting -916.99B in capital expenditures, free cash flow totaled 1.42T - equivalent to 25,940.34 per share.

Margins

Samsung Biologics Co.,Ltd. operates with a gross margin of 54.56, reflecting its pricing power and cost economics. The operating margin of 47.90 and net profit margin of 41.59 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Samsung Biologics Co.,Ltd.'s most recent stock split took place on October 30, 2025 with a 1000000:650391 split ratio.

Scores

Samsung Biologics Co.,Ltd. posts an Altman Z-Score of 14.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.